Cabozantinib: an Active Novel Multikinase Inhibitor in Renal Cell Carcinoma

por Tannir, Nizar M., Schwab, Gisela, Grünwald, Viktor
Publicado 2017

The scientific method: pillar and pitfall of cancer research

por Tu, Shi-Ming, Bilen, Mehmet Asim, Tannir, Nizar M
Publicado 2014

Molecular hallmarks of renal medullary carcinoma: more to c-MYC than meets the eye

por Msaouel, Pavlos, Walker, Cheryl L., Genovese, Giannicola, Tannir, Nizar M.
Publicado 2020

Real-World Experience With Cabozantinib in Metastatic Clear Cell Renal Cell Carcinoma: A Retrospective Analysis

por Lemke, Emily A., Shah, Amishi Y., Campbell, Matthew, Tannir, Nizar M.
Publicado 2019

Collision tumor of the kidney composed of clear cell carcinoma and collecting duct carcinoma: report of a case with unusual morphology and clinical follow-up

por Burch-Smith, Rhonda, Tannir, Nizar M, Resetkova, Erika, Tamboli, Pheroze, Rao, Priya
Publicado 2014

Plasma cytokine and angiogenic factors associated with prognosis and therapeutic response to sunitinib vs everolimus in advanced non-clear cell renal cell carcinoma

por Msaouel, Pavlos, Zurita, Amado J., Huang, Shixia, Jonasch, Eric, Tannir, Nizar M.
Publicado 2017

Clinical and Pathological Complete Remission in a Patient With Metastatic Renal Cell Carcinoma (mRCC) Treated With Sunitinib: Is mRCC Curable With Targeted Therapy?

por Shah, Amishi Y., Karam, Jose A., Lim, Zita D., Ng, Chaan S., Tannir, Nizar M.
Publicado 2015

Acute rhabdomyolysis with severe polymyositis following ipilimumab-nivolumab treatment in a cancer patient with elevated anti-striated muscle antibody

por Bilen, Mehmet Asim, Subudhi, Sumit K., Gao, Jianjun, Tannir, Nizar M., Tu, Shi-Ming, Sharma, Padmanee
Publicado 2016

Long-Term Survival Outcomes of Cytoreductive Nephrectomy Combined with Targeted Therapy for Metastatic Renal Cell Carcinoma: A Systematic Review and Individual Patient Data Meta-An...

por Esagian, Stepan M., Ziogas, Ioannis A., Kosmidis, Dimitrios, Hossain, Mohammad D., Tannir, Nizar M., Msaouel, Pavlos
Publicado 2021

Efficacy of Immune Checkpoint Inhibitors in Upper Tract Urothelial Carcinomas: Current Knowledge and Future Directions

por Thouvenin, Jonathan, Martínez Chanzá, Nieves, Alhalabi, Omar, Lang, Hervé, Tannir, Nizar M., Barthélémy, Philippe, Malouf, Gabriel G.
Publicado 2021

Racial Disparities in MiT Family Translocation Renal Cell Carcinoma

por Lu, Xiaofan, Tawanaie Pour Sedehi, Nassim, Su, Xiaoping, Yan, Fangrong, Alhalabi, Omar, Tannir, Nizar M, Malouf, Gabriel G
Publicado 2023

A Phase II Clinical Trial of Pembrolizumab Efficacy and Safety in Advanced Renal Medullary Carcinoma

por Nze, Chijioke, Msaouel, Pavlos, Derbala, Mohamed H., Stephen, Bettzy, Abonofal, Abdulrahman, Meric-Bernstam, Funda, Tannir, Nizar M., Naing, Aung
Publicado 2023

Response to post-axitinib treatment in patients with metastatic renal cell carcinoma

por Chittoria, Namita, Haddad, Housam, Elson, Paul, Tannir, Nizar M., Wood, Laura S., Dreicer, Robert, Garcia, Jorge A., Rini, Brian I., Jonasch, Eric
Publicado 2016

Pegilodecakin as monotherapy or in combination with anti‐PD‐1 or tyrosine kinase inhibitor in heavily pretreated patients with advanced renal cell carcinoma: Final results of cohor...

por Tannir, Nizar M., Papadopoulos, Kyriakos P., Wong, Deborah J., Aljumaily, Raid, Hung, Annie, Afable, Manuel, Kim, Jong Seok, Ferry, David, Drakaki, Alexandra, Bendell, Johanna, Naing, Aung
Publicado 2021

Primary Ewing Sarcoma/Primitive Neuroectodermal Tumor of the Kidney: The MD Anderson Cancer Center Experience

por Tarek, Nidale, Said, Rabih, Andersen, Clark R., Suki, Tina S., Foglesong, Jessica, Herzog, Cynthia E., Tannir, Nizar M., Patel, Shreyaskumar, Ratan, Ravin, Ludwig, Joseph A., Daw, Najat C.
Publicado 2020

COMPARZ Post Hoc Analysis: Characterizing Pazopanib Responders With Advanced Renal Cell Carcinoma

por Sternberg, Cora N., Motzer, Robert J., Hutson, Thomas E., Choueiri, Toni K., Kollmannsberger, Christian, Bjarnason, Georg A., Nathan, Paul, Porta, Camillo, Grünwald, Viktor, Dezzani, Luca, Han, Jackie, Tannir, Nizar M.
Publicado 2019

Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma

por Powles, Thomas, Choueiri, Toni K., Motzer, Robert J., Jonasch, Eric, Pal, Sumanta, Tannir, Nizar M., Signoretti, Sabina, Kaldate, Rajesh, Scheffold, Christian, Wang, Evelyn, Aftab, Dana T., Escudier, Bernard, George, Daniel J.
Publicado 2021

Correction to: Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma

por Powles, Thomas, Choueiri, Toni K., Motzer, Robert J., Jonasch, Eric, Pal, Sumanta, Tannir, Nizar M., Signoretti, Sabina, Kaldate, Rajesh, Scheffold, Christian, Wang, Evelyn, Aftab, Dana T., Escudier, Bernard, George, Daniel J.
Publicado 2021

Expression of long non-coding RNA MFI2-AS1 is a strong predictor of recurrence in sporadic localized clear-cell renal cell carcinoma

por Flippot, Ronan, Mouawad, Roger, Spano, Jean-Philippe, Rouprêt, Morgan, Compérat, Eva, Bitker, Marc-Olivier, Parra, Jérôme, Vaessen, Christophe, Allanic, Frederick, Manach, Quentin, Tannir, Nizar M., Khayat, David, Su, Xiaoping, Malouf, Gabriel G.
Publicado 2017

Long non-coding RNA profiling links subgroup classification of endometrioid endometrial carcinomas with trithorax and polycomb complex aberrations

por Jiang, Yunyun, Malouf, Gabriel G., Zhang, Jianping, Zheng, Xiaofeng, Chen, Yunxin, Thompson, Erika J., Weinstein, John N., Yuan, Ying, Spano, Jean-Philippe, Broaddus, Russell, Tannir, Nizar M., Khayat, David, Lu, Karen H., Su, Xiaoping
Publicado 2015